Clinical Trial Update: Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of the combination of Pozelimab and Cemdisiran versus continued Eculizumab or Ravulizumab in adults with Paroxy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Cemdisiran (cemdisiran)
• Eculizumab (eculizumab)
• Pozelimab
• Ravulizumab (ravulizumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: TERMINATED | Results posted: 2024-09-19